NCT06462144View on ClinicalTrials.gov

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

October 31, 2026

Conditions
Systemic Lupus Erythematosus (SLE)ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory Myopathy (IIM)
Interventions
DRUG

IMPT-514 CART Cell Injection

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Trial Locations (3)

200032

NOT_YET_RECRUITING

Zhongshan Hospital Fudan University., Shanghai

210008

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

221004

RECRUITING

The Affiliated Hospital Of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER